DK2118101T3 - IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer - Google Patents

IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer

Info

Publication number
DK2118101T3
DK2118101T3 DK08717546.9T DK08717546T DK2118101T3 DK 2118101 T3 DK2118101 T3 DK 2118101T3 DK 08717546 T DK08717546 T DK 08717546T DK 2118101 T3 DK2118101 T3 DK 2118101T3
Authority
DK
Denmark
Prior art keywords
imidazo
pyridine derivatives
glutaminyl cyclase
cyclase inhibitors
inhibitors
Prior art date
Application number
DK08717546.9T
Other languages
Danish (da)
English (en)
Inventor
Mirko Buchholz
Ulrich Heiser
Andre J Niestroj
Daniel Ramsbeck
Original Assignee
Probiodrug Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug Ag filed Critical Probiodrug Ag
Application granted granted Critical
Publication of DK2118101T3 publication Critical patent/DK2118101T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
DK08717546.9T 2007-03-09 2008-03-10 IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer DK2118101T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89390307P 2007-03-09 2007-03-09
PCT/EP2008/052799 WO2008110523A1 (en) 2007-03-09 2008-03-10 Imidazo [1,5-a] pyridine derivatives as inhibitors of glutaminyl cyclase

Publications (1)

Publication Number Publication Date
DK2118101T3 true DK2118101T3 (da) 2013-01-02

Family

ID=39456730

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08717546.9T DK2118101T3 (da) 2007-03-09 2008-03-10 IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer

Country Status (5)

Country Link
US (1) US7803810B2 (en:Method)
EP (1) EP2118101B1 (en:Method)
JP (1) JP5612860B2 (en:Method)
DK (1) DK2118101T3 (en:Method)
WO (1) WO2008110523A1 (en:Method)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2142513T3 (da) * 2007-04-18 2014-06-10 Probiodrug Ag Nitrovinyl-diamin-derivater som glutaminyl-cyclase-inhibitorer
JP5667440B2 (ja) * 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
US9512082B2 (en) * 2007-04-18 2016-12-06 Probiodrug Ag Inhibitors of glutaminyl cyclase
US8202897B2 (en) * 2007-04-18 2012-06-19 Probiodrug Ag Inhibitors of glutaminyl cyclases
JP5675342B2 (ja) * 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのシアノグアニジン誘導体
JP5675341B2 (ja) * 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体
EP2142536B1 (en) * 2007-04-20 2015-10-21 Probiodrug AG Aminopyrimidine derivatives as glutaminyl cyclase inhibitors
JP2011501652A (ja) * 2007-09-12 2011-01-13 プロビオドルグ エージー トランスジェニックマウス
EP2238252B1 (en) * 2008-01-14 2013-07-31 Probiodrug AG Mouse models carrying a knock-out mutation of the glutaminyl cyclase gene
AU2009273387B9 (en) 2008-07-21 2015-06-11 Vivoryon Therapeutics N.V. Diagnostic antibody assay
NZ598685A (en) 2009-09-11 2013-05-31 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US20110152341A1 (en) 2009-12-22 2011-06-23 Probiodrug Ag Cleavage of b-amyloid precursor protein
US20110212853A1 (en) 2010-02-18 2011-09-01 Probiodrug Ag Novel diagnostic method
SG192805A1 (en) 2011-03-16 2013-09-30 Probiodrug Ag Diagnostic antibody assay
PE20161384A1 (es) 2014-02-13 2016-12-28 Incyte Corp Ciclopropilaminas como inhibidores de lsd 1
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
RS59559B1 (sr) 2014-02-13 2019-12-31 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
EP3131399A4 (en) 2014-04-15 2018-02-14 Dow AgroSciences LLC Metalloenzyme inhibitor compounds as fungicides
CA2945671A1 (en) 2014-04-15 2015-10-22 Dow Agrosciences Llc Metalloenzyme inhibitor compounds as fungicides
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TWI687419B (zh) * 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
TWI714567B (zh) 2015-04-03 2021-01-01 美商英塞特公司 作為lsd1抑制劑之雜環化合物
TWI698435B (zh) * 2015-04-10 2020-07-11 英屬開曼群島商百濟神州有限公司 作為吲哚胺２,３-二加氧酶和/或色氨酸２,３-二加氧酶抑制劑之新穎之５或８-取代之咪唑並［１，５－ａ］吡啶
GB201511790D0 (en) * 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
HUE070538T2 (hu) 2015-08-12 2025-06-28 Incyte Holdings Corp Egy LSD1 inhibitor sói
BR112018071602B1 (pt) * 2016-04-29 2024-02-27 Iomet Pharma Ltd. Compostos de imidazopiridina substituídos, sua composição e seus usos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3- dioxigenase
WO2018054365A1 (en) 2016-09-24 2018-03-29 Beigene, Ltd. NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
CN111386114A (zh) 2017-11-25 2020-07-07 百济神州有限公司 作为吲哚胺2,3-双加氧酶的选择性抑制剂的新颖苯并咪唑
EP3521308B1 (en) 2018-01-31 2024-03-13 Vivoryon Therapeutics N.V. Humanized and de-immunized antibodies
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CN112110853A (zh) * 2020-09-23 2020-12-22 海南梵圣生物科技有限公司 一种合成3-羟基-2-吡啶甲酸及其衍生物的方法
CA3196901A1 (en) * 2020-11-02 2022-05-05 Kira A. Armacost Macrocyclic urea orexin receptor agonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI75569C (fi) 1981-06-22 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av terapeutiskt verkande imidazo/1,5-a/pyridiner.
US4444775A (en) * 1981-06-22 1984-04-24 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridines
US4409226A (en) * 1981-10-05 1983-10-11 Schering Corporation Imidazo[1,5-a]pyridines
US4470986A (en) * 1982-12-21 1984-09-11 Ciba-Geigy Corporation Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors
US5026712A (en) * 1985-06-05 1991-06-25 Schering Ag Novel imidazo[1,5-a]pyridines, useful as cardiovascular and CNS agents
ES2036128B1 (es) 1991-07-10 1993-12-16 Menarini Lab Procedimiento para la preparacion de 4-(imidazo)1,5-a)piridin-8l)-1,4-dihidropiridinas.
US6948038B2 (en) * 2001-07-24 2005-09-20 Microsoft Corporation System and method for backing up and restoring data
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
CA2505752A1 (en) * 2002-11-18 2004-06-03 Novartis Ag Imidazo[1,5a]pyridine derivatives and methods for treating aldosterone mediated diseases
DK1620082T3 (da) 2003-05-05 2010-08-16 Probiodrug Ag Medicinsk anvendelse af inhibitorer af glutaminyl- og glutamatcyclaser til behandling af Alzheimers sygdom og Downs syndrom
NZ568459A (en) * 2003-05-05 2009-06-26 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
US8338120B2 (en) * 2003-05-05 2012-12-25 Probiodrug Ag Method of treating inflammation with glutaminyl cyclase inhibitors
ZA200508439B (en) * 2003-05-05 2007-03-28 Probiodrug Ag Medical use of inhibitors of glutaminyl and glutamate cyclases
US7732162B2 (en) * 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
NZ546322A (en) 2003-10-15 2008-11-28 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
US20050171112A1 (en) * 2003-11-03 2005-08-04 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
US7667044B2 (en) * 2003-11-03 2010-02-23 Probiodrug Ag Compounds for the treatment of neurological disorders
EP1680120A2 (en) * 2003-11-03 2006-07-19 Probiodrug AG Combinations useful for the treatment of neuronal disorders
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
GB0704100D0 (en) 2006-03-17 2007-04-11 Vodafone Plc Improvements in an ehspa architecture
EP2082041B1 (en) * 2006-09-21 2018-03-14 Probiodrug AG Novel genes related to glutaminyl cyclase
US8420684B2 (en) * 2006-11-09 2013-04-16 Probiodrug Ag Inhibitors of glutaminyl cyclase
ES2481442T3 (es) * 2006-11-09 2014-07-30 Probiodrug Ag Inhibidores novedosos de glutaminil ciclasa
US9126987B2 (en) * 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
SI2121944T1 (sl) * 2007-01-19 2011-12-30 Probiodrug Ag In vivo presejalni modeli za zdravljenje Alzheimerjeve bolezni in drugih motenj, povezanih s QPCT

Also Published As

Publication number Publication date
US7803810B2 (en) 2010-09-28
US20080234313A1 (en) 2008-09-25
JP5612860B2 (ja) 2014-10-22
EP2118101B1 (en) 2012-09-26
EP2118101A1 (en) 2009-11-18
JP2010520869A (ja) 2010-06-17
WO2008110523A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
DK2118101T3 (da) IMIDAZO (1,5-A)-PYRIDinderivater som glutaminylcyclaseinhibitorer
DK2137184T3 (da) Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer
DK2124944T3 (da) Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
DK2160389T3 (da) Thioxoquinazolinonderivater som glutaminylcyclaseinhibitorer
DK2160380T3 (da) Cyano-guanidin derivater som glutaminyl cyclase inhibitorer
DK2201012T3 (da) Pyrrolo[2,3-d]pyrimidinderivater som proteinkinase b-hæmmere
DK2074122T5 (da) Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
DK2142514T3 (da) Thioureaderivater som glutaminylcyclase-inhibitorer
IL204720A0 (en) Imidazo [1, 2 - a] pyridine derivatives useful as alk inhibitors
DK2142513T3 (da) Nitrovinyl-diamin-derivater som glutaminyl-cyclase-inhibitorer
DK2094263T3 (da) 2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
DK2350075T3 (da) Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
DK1868999T3 (da) Pyridin-3-carboxamidderivater som omvendte CB1-agonister
DK2004654T3 (da) Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
HUS1200009I1 (hu) Pirrolo[2,3-B]piridin származékok, mint protein kináz inhibitorok
DK2069324T3 (da) Fusioneret aminopyridin som hsp90-inhibitorer
IL197393A0 (en) Pyridin-4-yl derivatives as immunomodulating agents
PL2069335T3 (pl) Pochodne pirydyn-3-ylu jako środki immunomodulujące
DK1846394T3 (da) Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
DK2142515T3 (da) Nitrovinyl-diaminderivater som glutaminyl-cyclase-inhibitorer
DK2078001T3 (da) Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer
IL205508A0 (en) 7 - azaindole derivatives as selective 11 - beta - hydroxysteroid dehydrogenase type 1 inhibitors
DE102008005493A8 (de) 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
DK2069310T3 (da) Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister
IL202769A0 (en) 6-PHENYL - 1H - IMIDAZO [4,5-c] PYRIDINE - 4 - CARBONITRILE DERIVATIVES AS CATHEPSIN INHIBITORS